BioVie Files 8-K on Jan 19 Event; Confirms Nasdaq Listing
Ticker: BIVIW · Form: 8-K · Filed: Jan 25, 2024 · CIK: 1580149
| Field | Detail |
|---|---|
| Company | Biovie Inc. (BIVIW) |
| Form Type | 8-K |
| Filed Date | Jan 25, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: compliance, administrative, corporate-governance
TL;DR
**BIVI filed an 8-K for an 'Other Event' on Jan 19, mostly administrative, confirming Nasdaq listing.**
AI Summary
BioVie Inc. filed an 8-K on January 25, 2024, reporting an 'Other Event' that occurred on January 19, 2024. This filing primarily updates administrative information, confirming its registration on The Nasdaq Stock Market, LLC under the trading symbol BIVI for its Class A Common Stock. For investors, this filing is largely administrative and doesn't signal any immediate operational or financial changes, but it reaffirms the company's compliance with SEC reporting requirements and its listing status.
Why It Matters
This filing confirms BioVie's continued compliance with SEC regulations and its listing on a major exchange, which is fundamental for investor confidence and liquidity.
Risk Assessment
Risk Level: low — The filing is administrative and does not disclose any new material risks or changes to the company's operations or financial health.
Analyst Insight
A smart investor would note this filing as routine compliance, confirming BioVie's listing status, but would not expect any immediate market-moving information from this specific 8-K.
Key Numbers
- $0.0001 — par value per share (par value of BioVie's Class A Common Stock)
Key Players & Entities
- BioVie Inc. (company) — the registrant filing the 8-K
- The Nasdaq Stock Market, LLC (company) — the exchange where BioVie's Class A Common Stock is registered
- BIVI (company) — the trading symbol for BioVie Inc.
- Nevada (company) — state of incorporation for BioVie Inc.
FAQ
What was the 'Date of earliest event reported' in this 8-K filing?
The 'Date of earliest event reported' was January 19, 2024, as stated in the filing.
What is the trading symbol and exchange for BioVie Inc.'s Class A Common Stock?
BioVie Inc.'s Class A Common Stock trades under the symbol BIVI on The Nasdaq Stock Market, LLC, according to the filing.
What is the par value per share for BioVie Inc.'s Class A Common Stock?
The par value per share for BioVie Inc.'s Class A Common Stock is $0.0001, as specified in the filing.
What is the business address of BioVie Inc. as reported in this 8-K?
The business address of BioVie Inc. is 680 W Nye Lane Suite 201, Carson City, NV 89703, as detailed in the filing.
Under which SEC Act is this current report filed?
This current report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 742 words · 3 min read · ~2 pages · Grade level 11.5 · Accepted 2024-01-25 17:00:41
Key Financial Figures
- $0.0001 — tered Class A Common Stock, par value $0.0001 per share BIVI The Nasdaq Stock Marke
Filing Documents
- bivi-20240119_8k.htm (8-K) — 26KB
- 0001520138-24-000045.txt ( ) — 195KB
- bivi-20240119.xsd (EX-101.SCH) — 3KB
- bivi-20240119_lab.xml (EX-101.LAB) — 33KB
- bivi-20240119_pre.xml (EX-101.PRE) — 22KB
- bivi-20240119_8k_htm.xml (XML) — 3KB
01
Item 8.01 Other Events. On January 19, 2024, a purported shareholder class action complaint, captioned Eric Olmstead v. BioVie Inc. et al. , No. 3:24-cv-00035, was filed in the U.S. District Court for the District of Nevada, naming BioVie Inc. (the "Company") and certain of its officers and/or directors as defendants. The lawsuit alleges that the Company made material misrepresentations and/or omissions of material fact relating to the Company's business, operations, compliance, and prospects, including information related to the study and trial of NE3107, in violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder. The class action is on behalf of purchasers of the Company's securities during the period from August 5, 2021 through November 29, 2023 and seeks unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including attorney's fees. The Company believes the lawsuit is without merit and intends to defend the case vigorously. At this early stage of the proceedings, the Company is unable to make any prediction regarding the outcome of the litigation. The Company does not intend to file further Current Reports on Form 8-K describing any additional lawsuits that may be filed that are based on allegations substantially similar to those described above. Cautionary Note Regarding Forward-Looking Statements This Current Report on Form 8-K contains forward-looking "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. In this report, forward-looking statements include, but are not limited to, those related to the outcome of the above-referenced shareholder class action. These are not statements of historical facts and are based on management's beliefs and assumptions and on information currently available. They are s
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 25, 2024 BIOVIE INC. By: /s/ Joanne Wendy Kim Name: Joanne Wendy Kim Title: Chief Financial Officer